Radiotherapy and risks of tumor regrowth or inducing second cancer

Cancer Nanotechnology

Volumn 2, Issue 1-6, 2011, Pages 81-93

  Moawad, Emad Y ^a,b  

^a Ain Shams University   (Egypt)

^b NONE   (Egypt)

Author keywords

Curing time; Lower irradiated dose treatment; Over irradiated dose treatment; Summation of tumor growth energy; Whole Body Cell Energy Burden

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CELL ENERGY; DOSIMETRY; MATHEMATICAL MODEL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RISK ASSESSMENT; SECOND CANCER;

EID: 81555198063     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-011-0018-4     Document Type: Article

References (31)

1. Balog J, Lucas D, DeSouza C et al (2005) Helical tomotherapy radiation leakage and shielding considerations. Med Phys 32: 710-719.
2. 131I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 42: 1251-1256, Abstract/Free Full Text.
3. Bolger BS, Symonds RP, Stanton PD et al (1996) Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 74: 1223-1226.
4. Bourhis J, Dendale R, Hill C etal (1996) Potential doubling time and clinical out come in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. In: J Radiat OncolBiol Phys 35: 47l-476.
5. Brenner DJ, Curtis RE, Hall EJ, Ron E (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88: 398-406.
6. Brenner DJ, Shuryak I, Russo S, Sachs RK (2007) Reducing second breast cancers: a potential role for prophylactic mammary irradiation. J Clin Oncol 25: 4868-4872.
7. Brown JM (1999) The hypoxic cell: a target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59: 5863-5870.
8. Coselmon MM, Moran JM, Radawski JD et al (2005) Improving IMRT delivery efficiency using intensity limits during inverse planning. Med Phys 32: 1234-1245.
9. Crooks SM, McAven LF, Robinson DF et al (2002) Minimizing delivery time and monitor units in static IMRT by leaf-sequencing. Phys Med Biol 47: 3105-3116.
10. Fisher DR (1994) Radiation dosimetry for radioimmunotherapy: an overview of current capabilities and limitations. Cancer 73: 905-911.
11. Fu W, Dai J, Hu Y et al (2004) Delivery time comparison for intensity-modulated radiation therapy with/without flattening filter: a planning study. Phys Med Biol 49: 1535-1547.
12. Gillies RJ, Gatenby RA (2007) Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 26(2): 311-317.
13. Gold DG, Neglia JP, Dusenbery KE (2003) Second neoplasms after megavoltage radiation for pediatric tumors. Cancer 97: 2588-2596.
14. Harlan LC, Potosky A, Gilliland FD et al (2001a) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93: 1864-1871.
15. Harlan LC, Potosky A, Gilliland FD et al (2001b) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93: 1864-1871.
16. Miralbell R, Lomax A, Cella L et al (2002) Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 54: 824-829.
17. Moawad E (2010) Isolated system towards a successful radiotherapy treatment. NMMI 44: 123-136.
18. Moawad EY, Mechanism of nuclear transmutations in the biological culture. MPM-D. 3 15: 30 HPS 2011 Annual Meeting hpschapters. org/2011AM/program/singlesession. php3?sessid=MPM-D.
19. Mohan R, Arnfield M, Tong S et al (2000) The impact of fluctuations in intensity patterns on the number of monitor units and the quality and accuracy of intensity modulated radiotherapy. Med Phys 27: 1226-1237.
20. O'Donoghue JA (1997) The response of tumors with Gompertzian growth kinetics to fractionated radiotherapy. Int J Radiat Biol 72: 325-339.
21. O'Donoghue JA, Sgouros G, Divgi CR, Humm JL (2000) Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 41: 538-547, Abstract/Free Full Text.
22. 131I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 45: 1059-1064, Abstract/Free Full Text.
23. Ron E (2006) Childhood cancer-treatment at a cost. J Natl Cancer Inst 98: 1510-1511.
24. Sachs RK, Brenner DJ (2005) Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 102: 13040-13045.
25. Schneider U, Besserer J (2010) Hypofractionated radiotherapy has the potential for second cancer reduction. Theor Biol Med Model 7: 4.
26. Stabin MG (1999) Internal dosimetry in the use of radiopharmaceuticals in therapy: science at a crossroads? Cancer Biother Radiopharm 14: 81-89, Medline.
27. Sullivan R, Graham CH (2007) Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 26(2): 319-331.
28. Terry NH, Meistrich ML, Roubein LD, Lynch PM, Dubrow RA, Rich TA (1995) Cellular kinetics in rectal cancer. BrJ Cancer 72: 435-441.
29. Thakur ML, Ron Coss (2003) Role of lipid-soluble complexes in targeted tumor therapy. J Nucl Med 44: 1293-1300.
30. Tsang RW, Fyles A W, Kirk bride P et al (1995) Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. In: J Radiat Oncol Biol Phys 32: 1319-1329.
31. Tubiana M (2009) Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 91(1): 4-15.